A Phase I Study of ONO-4685 Immunotherapy in People with T-Cell Lymphoma

Full Title

An Open-label, Multi-center, Non-randomized Phase I Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ONO-4685 Given as Monotherapy in Patients with Relapsed or Refractory T-cell Lymphoma

Purpose

The purpose of this study is to find the highest dose of the investigational drug ONO-4685 that can be given safely in people with cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma (PTCL) that came back or continued to grow despite treatment. ONO-4685 may strengthen the immune system’s ability to fight cancer cells by activating a patient’s own cells to destroy the tumor. It is given intravenously (by vein).